Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.
about
Update on clinical research and state of the art management of patients with advanced sarcomas and GISTCurrent management and prognostic features for gastrointestinal stromal tumor (GIST)Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study.Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylateExpression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors, leiomyomas and schwannomas.Expressions of sonic hedgehog, patched, smoothened and Gli-1 in human intestinal stromal tumors and their correlation with prognosis.Expression of Ets-1 proto-oncoprotein in gastrointestinal stromal tumors, leiomyomas and schwannomasEfficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis.Pediatric and wild-type gastrointestinal stromal tumor: new therapeutic approaches.Imaging gastrointestinal stromal tumors.Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate.Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal.Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours.Imatinib in gastrointestinal stromal tumour: Northern Cancer Network experienceConsensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.Expression of angiopoietin-1, 2 and 4 and Tie-1 and 2 in gastrointestinal stromal tumor, leiomyoma and schwannomaClinical manifestations and prognostic factors in patients with gastrointestinal stromal tumorsGastrointestinal stromal tumours: consensus statement on diagnosis and treatment.Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II TrialA Guideline for the Management of Gastrointestinal Stromal Tumour (GIST).Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue SarcomasFuture options for imatinib mesilate-resistant tumors.Imatinib mesilate for the treatment of gastrointestinal stromal tumour.Gastrointestinal stromal tumors: key to diagnosis and choice of therapy.Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study).The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.Colorectal gastrointestinal stromal tumors: a brief review.Clinicopathological features and prognosis of colonic gastrointestinal stromal tumors: evaluation of a pooled case series.Imatinib mesylate for the treatment of gastrointestinal stromal tumor.The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy.FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway.Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.The value of (18) F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta-analysis.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.
P2860
Q28073290-336A46F3-5F7C-412C-9FFF-CE0A698D71FAQ28391684-EFA8642B-BE61-4A0F-B86B-7C6BF9744820Q33311606-C0A14493-C918-445B-9F32-48DF6C83ADB7Q33343936-54E535BB-F9D3-40CE-8DE0-81FFCDE0A156Q33866421-EB82F5AF-1B38-4302-9999-C619B82F5CA0Q33867290-BDC76762-B00E-4846-8DF4-8F971B86F180Q33869014-9B011452-960F-4D84-8781-CD2FA73B3C6DQ33869254-80E34BE9-DB4D-4E14-8B85-6678ED87F271Q34012831-003989F0-9446-436E-937F-09765B604999Q34102055-8CD219AF-FEEA-4F7C-A13F-9965B510D227Q34171517-AC6712C1-55F9-4CCB-9D74-D7A78AB77870Q34414114-91119C94-5B0A-45E3-BDB6-E04835D6863CQ34596126-164824FF-86FB-4578-98EE-B31F3879966DQ35026332-F3E4820C-75BD-47EE-A1F2-7A1A4C54CDECQ35069149-7277FA68-3EF6-4C01-80BC-9998AB1A85B3Q35572873-50CC36B3-D9C8-4995-B77A-A1A80A3AEBA0Q36076570-01960440-5CC6-49CC-959E-65038F8A5087Q36086354-94A8742D-42B1-469E-B28F-BB770C3EF8ADQ36179058-8C3A471B-0A2A-4657-AFB4-4583736014E6Q36180566-C2A175A0-CCE9-4A82-84F2-8B58E4D947FEQ36426847-FB7DBD4E-F231-4C58-854A-19E520AA2B5AQ36499861-23468E9A-0412-491E-98BE-A28DA54A7A92Q36674146-50FAF8F2-1069-4A65-9E6F-35C41CA07E55Q36674450-B8574F7A-80D7-461A-AA5D-85881D08100BQ36964688-5D000E9E-06B9-4DE0-8A12-12DD1AC9A913Q37142082-751E43BA-7E1A-497B-AE0C-34235F40E295Q37176371-6D292242-6557-4D36-80FD-D8179226B9ABQ37182155-3BF091F9-4309-4251-80F0-CF97E6887772Q37252029-C9C9EDA6-E58F-4276-BC94-C3099A0FDF22Q37342909-2FE0D935-340B-43AE-97A8-8384205EC343Q37427577-D9783DD6-C12F-4397-ADF0-EB66992A07C5Q37458021-90E88DD4-86DD-4D30-8824-5F37B2410894Q37752353-4232A0CD-EDC5-4C9D-9FAC-05A4E92D5CF8Q37948132-28A32F26-7899-4998-9EE7-685B2CF5103FQ38034434-6B6BA1E9-E29B-4896-8848-75BBFC9A50D8Q38100719-F694FD94-4946-4E21-A55A-4C3A8F751E22Q38112821-E058DC84-305A-4995-A72B-AF9F6A74FB42Q38380851-65C887A2-94B8-437E-8CAE-528A0B1FEE33Q38661189-2BD3B6D3-7A7E-49F0-B722-53BF85EEBDFCQ38925022-C0E2A146-0023-4D83-92C4-906FDC4636BB
P2860
Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Soft tissue leiomyosarcomas an ...... multidrug resistance proteins.
@en
Soft tissue leiomyosarcomas an ...... multidrug resistance proteins.
@nl
type
label
Soft tissue leiomyosarcomas an ...... multidrug resistance proteins.
@en
Soft tissue leiomyosarcomas an ...... multidrug resistance proteins.
@nl
prefLabel
Soft tissue leiomyosarcomas an ...... multidrug resistance proteins.
@en
Soft tissue leiomyosarcomas an ...... multidrug resistance proteins.
@nl
P2093
P1476
Soft tissue leiomyosarcomas an ...... multidrug resistance proteins.
@en
P2093
E van den Berg
G H Torn Broers
H J Hoekstra
M F Mastik
R J Scheper
W M Molenaar
W T van der Graaf
P304
P356
10.1200/JCO.2000.18.18.3211
P407
P577
2000-09-01T00:00:00Z